Table 3.
Antidiabetic drug | Baseline | Week 52 | ||||||
---|---|---|---|---|---|---|---|---|
FAS (n = 4,514) | FAS (n = 3,876) | With insulin (n = 354) | Without insulin (n = 3,522) | |||||
Odds ratio | P‐value | Odds ratio | P‐value | Odds ratio | P‐value | Odds ratio | P‐value | |
Sulfonylurea | 0.98 | 0.92 | 2.22 | <0.001 | 1.10 | 0.79 | 4.01 | <0.001 |
Glinide | 1.66 | 0.51 | 2.05 | 0.26 | 0.83 | 0.86 | 4.14 | 0.07 |
α‐GI | 0.68 | 0.13 | 0.74 | 0.28 | 0.72 | 0.35 | 0.73 | 0.49 |
Metformin | 1.55 | 0.036 | 1.10 | 0.71 | 1.18 | 0.64 | 0.93 | 0.84 |
Pioglitazone | 0.73 | 0.37 | 1.59 | 0.18 | 0.54 | 0.42 | 2.18 | 0.043 |
Insulin | 11.59 | <0.001 | 17.75 | <0.001 | – | – | – | – |
Data are shown as odds ratio. α‐GI, alpha‐glucosidase inhibitor; FAS, full analysis set.